Gapping down
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- BNTX -4%, THS -3.4%, AMR -2.5%, SHO -1.4%, AXSM -1.1%, CNA -0.9%, SAVE -0.8%
Other news:
- GLYC -76.8% (announces results of pivotal phase 3 Study of uproleselan in relapsed/refractory (R/R)
- AML; did not achieve a statistically significant improvement)
- EYPT -32.9% (topline data from the phase 2 pavia trial of Duravyu in non-proliferative diabetic retinopathy)
- MPW -15.8% (Steward Health Care finalizing financing deal with Medical Properties Trust to support its restructuring)
- LAZR -7.7% (files mixed securities shelf offering; confirmed after the close a restructuring plan)
- ADCT -4.7% (Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA in Patients with Relapsed/Refractory Marginal Zone Lymphoma; agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of $4.90/share)
- MTH -3.1% (commenced an offering of $500 mln aggregate principal amount of its Convertible Senior Notes due 2028)
- SO -2.5% (offering of $1.1 billion in aggregate principal amount of Convertible Senior Notes due June 15, 2027)
- PAC -2.3% (reports April traffic)
- BMRN -2.3% (reports New Data for BioMarin's VOXZOGO (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting)
- ADTN -1.7% (to take a $293 mln goodwill impairment charge in Q1)